Molnupiravir is currently being developed by two companies, Ridgeback Biotherapeutics in Germany and Merck in the US, with the aim of treating Covid-19 patients.
1. What is Molnupiravir?
According to Wikipedia, Molnupiravir is a prodrug of N4-hydroxycytidine, an antiviral drug that was originally developed to treat influenza.
The New York Times reported that Molnupiravir is also known as MK-4482. This drug is currently being developed by two companies, Ridgeback Biotherapeutics in Germany and Merck in the US, for use in treating Covid-19 patients. Accordingly, Molnupiravir is a product researched and developed by the American pharmaceutical company Merck and the German company Ridgeback.
According to the results of studies on human and animal lung cells, Molnupiravir can be used in oral tablet form instead of intravenous injection like Remdesivir. That is, patients with mild Covid-19 will use this drug to stop the disease from developing.
2. How effective is molnupiravir in treating Covid-19?
Director of the Central Lung Hospital GS-Dr Nguyen Viet Nhung said that according to the assignment of the Ministry of Health, this unit has carried out a clinical trial to study the antiviral drug Molnupiravir. The results of this study initially gave relatively positive results.
Specifically, Professor Nhung said that within 5 days of using Molnupiravir, the rate of viral negatives was very high, but to use this drug on a large scale, it is necessary to conduct a larger-scale clinical trial.
In Vietnam, the government is sponsored by a business with more than 2.3 million Molnupiravir 400 mg capsules. And these drugs, starting on August 27, have been tested on 116,000 Covid-19 patients in the community.
Besides imported drugs, there are now domestic enterprises producing Molnupiravir and ready to sponsor the first 16,000 doses. It is known that by September 5, 2021, this enterprise will provide another 100,000 doses (total of 2 batches is 2,320,000 Molnupiravir 400mg tablets).
3. Which F0 is used Molnupiravir?
Molnupiravir users are mild cases of Covid-19 by rapid test or RT-PCR. And this group of people must be between the ages of 18 and 65 and they agree to participate in the use of Molnupiravir. Along with that, when using this drug, people with Covid-19 will be controlled by authorities in the community.
In which, F0 in mild form are those who have symptoms such as dry cough, fever, sore throat, fatigue, body aches, nasal congestion, headache, numbness of tongue, breathing rate less than 20 times per minute, blood cell concentration. oxygen in the blood when breathing air ≥ 96% and no signs of hypoxia or pneumonia.
Currently, the Department of Health of Ho Chi Minh City has distributed the quantity of Molnupiravir as well as guided the process of receiving and dispensing to the districts, Thu Duc city. At the same time, the Department also suggested that medical centers quickly receive and distribute this medicine to F0 cases isolated at home in the area under their management in the spirit of the right people, the right subjects according to the instructions of the Ministry of Health. Department.
Đọc bài viết bằng Tiếng Việt tại đây